Progesterone is often included in a menopause plan for a specific reason: protecting the uterine lining when a person with a uterus uses systemic estrogen. It should not be reduced to a generic balancing ingredient.
The product, route and schedule matter. This guide explains the questions to ask; it does not select a dose, change a regimen or tell you to add progesterone without a clinician’s assessment.
In this entry
Understand the family name
Progestogen is the umbrella term covering progesterone and related progestins. Different products and schedules may be used in different circumstances. Micronized progesterone is available in FDA-approved medicines, including the brand Prometrium and appropriate generic products.
A bioidentical description does not mean the medicine must be compounded. Read the regulatory brief if a provider’s wording leaves that impression.
Ask why it is included in your plan
Systemic estrogen can stimulate the endometrium. An appropriate progestogen regimen reduces the risk associated with unopposed estrogen in a person who has a uterus. The clinician should explain how your prescription addresses that risk.
If you have had a hysterectomy, clarify the operation and relevant history. If you are using low-dose local vaginal estrogen, the progestogen question is generally different from systemic therapy. Do not make either decision solely from a checklist on a sales page.
Do not treat all progesterone routes as equivalent
A compounded skin cream that contains progesterone should not automatically be considered equivalent to a studied regimen for uterine protection. The presence of the ingredient does not establish adequate absorption or clinical effect.
Ask what evidence supports the prescribed product and what happens if you cannot tolerate it. Do not simply drop it while continuing systemic estrogen. If a clinician changes the route or schedule, get the new directions in writing and confirm which previous instructions no longer apply.
Read the label and discuss adverse effects
Some progesterone products can cause drowsiness or dizziness. The exact product information and clinician’s instructions should guide timing and precautions. Tell the pharmacist about allergies and ask about inactive ingredients, because formulations can differ.
Discuss any new or unexpected bleeding rather than assuming it is harmless. The clinician can explain what might occur with a particular regimen and when evaluation is needed. Heavy bleeding with faintness or severe pain needs prompt medical attention.
Know what changed in 2026
Prometrium was among the products listed in the FDA’s February 2026 menopause labeling update. That action did not turn every progesterone preparation into an approved medicine or eliminate the need for an individualized risk discussion.
The 2026 update links the agency’s product list. For a provider comparison, the Alloy review discusses a menu where progesterone is listed separately, while Winona’s review raises the questions relevant to compounded formats. Always compare the complete regimen, including the cost of each required medicine.
If you have had surgery, the hysterectomy and HRT guide explains which records matter. Use the unexpected bleeding checklist to prepare a report if a new symptom occurs.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.